Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use

Contraception

Volumn 81, Issue 1, 2010, Pages 57-61

  Wiegratz, Inka ^a   Stahlberg, Skadi ^a   Manthey, Torsten ^a   Sänger, Nicole ^a   Mittmann, Katrin ^b   Palombo Kinne, Ernesta ^b   Mellinger, Uwe ^b   Lange, Evelyn ^b   Kuhl, Herbert ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Dienogest; Ethinyl estradiol; Extended cycle regimen; Lipid metabolism; Oral contraceptives

Indexed keywords

CHOLESTEROL; ETHINYL ESTRADIOL PLUS DIENOGEST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LOW DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MULTICENTER STUDY; ORAL CONTRACEPTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TINNITUS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL BLOOD LEVEL;

ADOLESCENT; ADULT; CHOLESTEROL; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; ETHINYL ESTRADIOL; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; LIPID METABOLISM; NANDROLONE; PATIENT SELECTION; TRIGLYCERIDES;

EID: 71149087931     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.07.011     Document Type: Article

References (25)

1. Petitti D.B., Sidney S., and Quesenberry C.P. Oral contraceptive use and myocardial infarction. Contraception 57 (1998) 143-155
2. Khader Y.S., Rice J., John L., and Abueita O. Oral contraceptive use and the risk of myocardial infarction: a meta-analysis. Contraception 68 (2003) 11-17
3. Baillargeon J.P., McClish D.K., Essah P.A., and Nestler J.E. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90 (2005) 3863-3870
4. Tanis B.C., van den Bosch M.A.A.J., Kemmeren J.M., et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 345 (2001) 1787-1793
5. Margolis K.L., Adami H.O., Luo J., Ye W., and Weiderpass E. A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril 88 (2007) 310-316
6. Crook D., and Godsland I. Safety evaluation of modern oral contraceptives. Contraception 57 (1998) 189-201
7. Godsland I.F. Biology: risk factor modification by OCs and HRT lipids and lipoproteins. Maturitas 47 (2004) 299-303
8. Wiegratz I., and Kuhl H. Progestogen therapies: differences in clinical effects?. Trends Endocrinol Metab 15 (2004) 277-285
9. Wiegratz I., and Kuhl H. Long-cycle treatment with oral contraceptives. Drugs 64 (2004) 2447-2462
10. Sulak P.J., Kuehl T.J., Ortiz M., and Shull B.L. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 186 (2002) 1142-1149
11. Wiegratz I., Hommel H.H., Zimmermann T., and Kuhl H. Attitudes of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 69 (2004) 37-42
12. Kuhl H., and Wiegratz I. Metabolic and clinical effects of progestogens. Eur J Contracept Reprod Health Care 11 (2006) 153-161
13. Wiegratz I., Lee J.H., Kutschera E., Bauer H.H., et al. Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception 65 (2002) 223-229
14. März W., Jung-Hoffmann C., Heidt F., Gross W., and Kuhl H. Changes in lipid metabolism during 12 months of treatment with two oral contraceptives containing 30 μg ethinylestradiol and 75 μg gestodene or 150 μg desogestrel. Contraception 41 (1990) 245-258
15. Rubeck Petersen K., Skouby S.O., and Gronholt Pedersen R. Desogestrel and gestodene in oral contraceptives: 12 months' assessment of carbohydrate and lipoprotein metabolism. Obstet Gynecol 78 (1991) 666-672
16. Song S., Chen J.K., Yang P.J., et al. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. Contraception 45 (1992) 523-532
17. Oelkers W., Foidart J.M., Dombrovicz N., Welter A., and Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 80 (1995) 1816-1821
18. Kuhl H., Jung-Hoffmann C., Fitzner M., März W., and Gross W. Short- and long-term effects on lipid metabolism of oral contraceptives containing 30 μg ethinylestradiol and 150 μg desogestrel or 3-keto-desogestrel. Horm Res 44 (1995) 121-125
19. Wiegratz I., Jung-Hoffmann C., Gross W., and Kuhl H. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Contraception 58 (1998) 83-91
20. van der Mooren M.J., Klipping C., van Aken B., Helmerhorst E.M., Spielmann D., and Kluft C. A comparative study of the effects of gestodene 60 μg/ethinylestradiol 15 μg and desogestrel 150 μg/ethinylestradiol 20 μg on hemostatic balance, blood lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care 4 Suppl 2 (1999) 27-35
21. Knopp R.H., Broyles F.E., Cheung M., Moore K., Marcovina S., and Chandler W.L. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception 63 (2001) 1-11
22. Klipping C., and Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 71 (2005) 409-416
23. Wiegratz I., Hertwig B., Jung-Hoffmann C., and Kuhl H. Inhibition of low-density lipoprotein oxidation in vitro and ex vivo by several estrogens and oral contraceptives. Gynecol Endocrinol 10 Suppl 2 (1996) 149-152
24. Cachrimanidou A.C., Hellberg D., Nilsson S., von Schoulz B., Crona N., and Siegbahn A. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive. Contraception 50 (1994) 153-165
25. Bonassi Machado R., Fabrini P., Machado Cruz A., Maia E., and da Cunha Bastos A. Clinical and metabolic aspects of the continuous use of contraceptive association of ethinyl estradiol (30 μg) and gestodene (75 μg). Contraception 70 (2004) 365-370